Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

We have observed that systemic administration of cannabinoid CB1 antagonists exerts antiparkinsonian effects in rats with very severe nigral lesion (>95% cell loss), but not in rats with less severe lesion (85–95% cell loss). Local injections into denervated striatum and corresponding globus pall...

Full description

Bibliographic Details
Main Authors: Emilio Fernandez-Espejo, Isabel Caraballo, Fernando Rodriguez de Fonseca, Fadwa El Banoua, Belen Ferrer, Juan A. Flores, Beatriz Galan-Rodriguez
Format: Article
Language:English
Published: Elsevier 2005-04-01
Series:Neurobiology of Disease
Subjects:
Parkinson
Cannabinoid
SR141716A
AM251
CB1 receptor
Anandamide
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996104002670

Internet

http://www.sciencedirect.com/science/article/pii/S0969996104002670

Similar Items